We just returned from KVK Tech where we reviewed the Formulation progress of our Oral COVID therapeutic, SJP-002C.

Everything is progressing as planned and we expect to be making our FDA submission in 6-9 months. Our phase 2 clinical trial is progressing and we are starting discussions with licensing partners around the world.

Our oral COVID therapeutic has the potential to be a market disruptor of Pfizer's Paxlovid (Projected 2022 revenue of $22B) with the following points of differentiation:

• Cost
• Safety
• Drug:Drug Interaction Profile
• Broader Spectrum for future variants/mutations
• Ease of distribution

We expect our efforts to be rewarded with 10-30% of the future oral COVID therapeutic market. At our suggested price point this could result in $335M to $1B in annual revenue.

Our current Wefunder convertible note campaign ends on July 31st! The best time is invest is now for we will be starting another campaign at a much higher valuation.

Thank you for your continued support!

Jim